Loading clinical trials...
Loading clinical trials...
Fecal Virome Transplantation (FVT) has in small studies shown benefit in the treatment of recurrent C. difficile infection. In the VISION study we will treat patients with recurrent C. difficile infection with FVT capsules and compare the treatment with Fecal Microbiota Transplantation (FMT) capsules. Both will be following af standard treatment of antibiotics (Vancomycin)
In the VISION study we will treat patients with recurrent C. difficile infection (CDI) with FVT capsules and compare the treatment with Fecal Microbiota Transplantation (FMT) capsules. Patients will be randomised to receive either FMT or FTV capsules. Patients will be followed for one year to investigate the risk of a new recurrence of CDI. Patients and researchers involved in the treatment of the patients will be blinded to the treatment
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Copenhagen University Hospital Hvidovre
Hvidovre, Denmark
Start Date
May 1, 2024
Primary Completion Date
January 1, 2026
Completion Date
December 31, 2026
Last Updated
May 3, 2024
40
ESTIMATED participants
Fecal Virome Transplantation
OTHER
Fecal microbiota Transplantation
OTHER
Lead Sponsor
Copenhagen University Hospital, Hvidovre
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions